Evaluation of Androgen Receptor in Breast Carcinoma and its Correlations with Er, Pr, Her2/Neu, Triple Negative Receptor Status and Clinical Parameters

  • Avanish Kumar Saxena Professor, Department of Surgery S.N. Medical College, Agra
  • Mayank Agarwal Senior Resident, Department of Anaesthesia, S.N Medical College, Agra, UP, India.
  • Juhi Singhal Associate Professor, Department of Surgery S.N. Medical College, Agra
  • Amrita Gupta Assistant Professor, Department of Anaesthesia SN Medical College, Agra
Keywords: Androgen Receeptor, Estrogen Receptor, Triple Negative , Breast Cancer

Abstract

Background: Breast cancer is the second most common malignancy in Indian women. Among the members of the steroid receptor superfamily the role of estrogen and progesterone receptors (ER and PR) is well established in breast cancer in predicting the prognosis and management of therapy, however, little is known about the clinical significance of androgen receptor (AR) in breast carcinogenesis. The present study was aimed to evaluate the expression of AR in breast cancer and to elucidate its clinical significance by correlating it with other hormonal receptors and clinical parameters. Methods: It was a prospective study which include 30 patients of histopathologically proven breast cancer  admitted to department of surgery at  S.N Medical College Agra .Expression of AR, ER, PR, HER2/ neu receptor  by immunohistochemistry (IHC) and clinical parameters were studied. Results: AR expression is related to ER(P<0.015), PR(p<0.008) and triple negative breast cancer patients (p <0.008). There is significant correlation between AR and menopausal status(p<0.006) while  no significant correlation was found with age and parity. Conclusions: Since there is significant association of AR  in triple negative and post-menopausal women so we can say that AR expression possibly help in confirming their predictive role for therapeutic response in breast cancer patients

Downloads

Download data is not yet available.

References

1. Ashwani K. Mishra, Usha Agrawal, ShivaniNegi, Anju Bansal, R. Mohil, ChintamaniChintamani, Amar Bhatnagar, Dinesh Bhatnagar&SunitaSaxena. Expression of androgen receptor in breast cancer & its correlation with other steroid receptors & growth factors. Indian J Med Res2012; 135:843-852
2. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ, Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid BiochemMolBiol 1995; 52:459-467.
3. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas. Potential relevance to new therapeutic strategies. Cancer 2003; 98:703-11.
4. Tung, N. What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positiveearly breast cancer? J. Clin. Oncol. 2013, 31, 1391-1397
5. McGuire, W.L. Estrogen receptors in human breast cancer. J. Clin. Investig. 1973, 52, 73-77.
6. Regan, M.M.; Neven, P.; Giobbie-Hurder, A.; Goldhirsch, A.; Ejlertsen, B.; Mauriac, L.; Forbes, J.F.; Smith, I.;Lang, I.;Wardley,
A.; et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: The BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011, 12, 1101-1108.
7. Ortmann, O.; Pagani, O.; Jones, A.; Maass, N.; Noss, D.; Rugo, H.; van de Velde, C.; Aapro, M.; Coleman, R. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treat. Rev. 2010,37,
8. Luis O Gonzalez, Maria D Corte, Julio Vazquez, Sara Junquera, Rosario Sanchez, Ana C Alvarez, Juan C Rodriguez, Maria L Lamelas and Francisco J Vizoso. Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, andexpression of metalloproteases and their inhibitors. BMC Cancer 2008;8:149-158
9. Nahleh, Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: An unchartered territory. Future Oncol. 2008, 4, 15-21.
10. Hu R, Dawood S, Holmes MD, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011; 17:1867-74.
11. Foster PA. Steroid metabolism in breast cancer. Minerva Endocrinol. 2008;33:27-37
12. Hao, Y.; Montiel, R.; Li, B.; Huang, E.; Zeng, L.; Huang, Y. Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: A meta-analysis. Breast Cancer Res. Treat. 2010, 124, 815-820.
13. Raina V, Bhutani M, Beedi Rajeev Sharma, atul et al clinical features and prognostic factors of early breast cancer at major cancer centre in north india journal cancer2005;42:40-5.
14. Li, C.I.; Daling, J.R.; Malone, K.E. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J. Clin. Oncol. 2003, 21, 28-34
15. Cronin, K.A.; Harlan, L.C.; Dodd, K.W.; Abrams, J.S.; Ballard-Barbash, R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Investig. 2010,28, 963-968.
16. Chan, A.; McGregor, S.R. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab. Intern. Med. J. 2011, 42, 267-274.
17. Cochrane, D.R.; Bernales, S.; Jacobsen, B.M.; Cittelly, D.M.; Howe, E.N.; D'Amato, N.C.; Spoelstra, N.S.; Edgerton, S.M.; Jean, A.; Guerrero, J.; et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014, 16, R7.
18. Wang, Y.; Localio, R.; Rebbeck, T.R. Evaluating bias due to population stratification in epidemiologic studies of gene-gene or gene-environment interactions. Cancer Epidemiol. Biomark. Prev. 2006, 15, 124-132.
19. Millikan, R.C. Re: Population stratification in epidemiologic studies of common genetic variants and cancer: Quantification of bias. J. Natl. Cancer Inst. 2001, 93, 156-158.
20. Ogawa Y1, Hai E, Matsumoto K, Ikeda K, Tokunaga S, Nagahara H, Sakurai K, Inoue T, Nishiguchi Y. 18 Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkersInt J Clin Oncol. 2008 Oct;13(5):431-5.
21. Sandeep Sanga1,2, Bradley M Broom3, Vittorio Cristini2,1 and Mary E Edgerton Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family BMC Medical Genomics 2009, 2:59
22. Gucalp, A.; Traina, T.A. Triple-negative breast cancer: Role of the androgen receptor. Cancer J. 2010, 16, 62-65.
23. Narayanan, R.; Ahn, S.; Cheney, M.D.; Yepuru, M.; Miller, D.D.; Steiner, M.S.; Dalton, J.T. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial: Mesenchymal stem cell signaling. PLoS ONE 2014, 9, e103202.
24. Chottanapund, S.; Van Duursen, M.B.; Navasumrit, P.; Hunsonti, P.; Timtavorn, S.; Ruchirawat, M.; Van den Berg, M. Effect of androgens on different breast cancer cells co-cultured with or without breast adipose fibroblasts. J. Steroid Biochem. Mol. Biol. 2013, 138, 54-62
Published
2017-09-23
How to Cite
1.
Saxena A, Agarwal M, Singhal J, Gupta A. Evaluation of Androgen Receptor in Breast Carcinoma and its Correlations with Er, Pr, Her2/Neu, Triple Negative Receptor Status and Clinical Parameters. IABCR [Internet]. 23Sep.2017 [cited 21Jul.2019];3(3):48-1. Available from: https://iabcr.org/index.php/iabcr/article/view/53